| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Skyrizi | $2.73B | $3.21B | $3.78B | $3.43B | $4.42B | $4.71B | $5.01B | $4.48B |
| Rinvoq | $1.43B | $1.61B | $1.83B | $1.72B | $2.03B | $2.18B | $2.37B | $2.12B |
| All other | $810M | $726M | $752M | $1.25B | $603M | $660M | $617M | $1.03B |
| Botox Therapeutic | $814M | $848M | $873M | $866M | $928M | $985M | $990M | $1.01B |
| Vraylar | $774M | $875M | $924M | $765M | $900M | $934M | $1.02B | $905M |
| Venclexta | $637M | $677M | $655M | $665M | $691M | $726M | $710M | $770M |
| Humira | $2.81B | $2.23B | $1.68B | $1.12B | $1.18B | $993M | $1.25B | $688M |
| Botox Cosmetic | $729M | $671M | $687M | $556M | $692M | $637M | $717M | $668M |
| Imbruvica | $833M | $828M | $848M | $738M | $754M | $706M | $671M | $556M |
| Mavyret | $369M | $302M | $291M | $306M | $375M | $312M | $324M | $351M |
| Ubrelvy | $231M | $269M | $303M | $240M | $338M | $354M | $339M | $339M |
| Qulipta | $150M | $176M | $201M | $193M | $267M | $288M | $288M | $296M |
| Other Aesthetics | $318M | $310M | $332M | $315M | $327M | $303M | $320M | $286M |
| Linzess | $221M | $234M | $233M | $148M | $258M | $326M | $175M | $283M |
| Juvederm Collection | $343M | $258M | $279M | $231M | $260M | $253M | $249M | $232M |
| Vyalev | — | — | — | $63M | $98M | $138M | $183M | $201M |
| Elahere | — | — | — | $179M | $159M | $170M | $182M | $198M |
| Other Neuroscience | $62M | $56M | $56M | $155M | $55M | $46M | $47M | $125M |
| Epkinly | $36M | $43M | $40M | $51M | $70M | $69M | $81M | $83M |
| Total | $14.46B | $14.46B | $15.1B | $13.34B | $15.42B | $15.78B | $16.62B | $15B |